Valuation : ORIC Pharmaceuticals, Inc.

Market Cap 1.33B 1.15B 1.08B 986M 1.84B 126B 1.85B 12.75B 4.95B 64.57B 5.01B 4.9B 208B P/E 2026 *
-8.47x
P/E 2027 * -7.81x
Enterprise Value 1.33B 1.15B 1.08B 986M 1.84B 126B 1.85B 12.75B 4.95B 64.57B 5.01B 4.9B 208B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
1 week-3.21%
Current month-0.90%
1 month+4.36%
3 months+58.76%
6 months-5.13%
Current year+59.49%
1 week 10.76
Extreme 10.76
11.36
1 month 10.76
Extreme 10.76
12.48
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 2018-05-06
Director of Finance/CFO 52 2019-08-31
Chief Tech/Sci/R&D Officer - 2025-08-17
Director TitleAgeSince
Chairman 68 2018-03-06
Director/Board Member 47 2018-05-06
Director/Board Member 62 2020-01-31
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-3.21%+20.93%+30.24% 1.33B
-1.79%-2.27%+50.90%+89.03% 67.98B
-2.06%-0.18%+41.53%+88.17% 64.94B
-0.31%+6.54%-11.39%+457.82% 27.58B
-3.00%-2.90%+39.40%+9.41% 25.74B
+0.86%+1.65%+0.25%-14.78% 26.06B
-1.46%+0.42%+24.07%-18.70% 20.09B
-2.96%-15.21%+210.71%+370.84% 17.16B
-1.49%-4.88%-0.41%+530.26% 14.92B
-0.20%+8.37%+57.87%+159.50% 14.62B
Average -1.38%+0.26%+43.39%+170.18% 31.01B
Weighted average by Cap. -1.52%+0.18%+42.19%+144.53%

Financials

2026 *2027 *
Net sales - -
Net income -166M -143M -134M -122M -229M -15.64B -230M -1.58B -615M -8.02B -622M -608M -25.85B -197M -169M -159M -146M -272M -18.59B -273M -1.88B -731M -9.54B -739M -723M -30.72B
Net Debt - -
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
26-09-04 €11.01 +0.78%
26-09-03 €10.92 -3.06%
26-09-02 €11.27 +2.08%
26-09-01 €11.04 -0.63%
26-08-31 €11.11 -2.33%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.86USD
Average target price
20.67USD
Spread / Average Target
+60.71%

Quarterly revenue - Rate of surprise